Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 9 (September)

1. Enzyme Fragment Complementation Binding Assay for p38alpha Mitogen-Activated Protein Kinase to Study the Binding Kinetics of Enzyme Inhibitors.
   Assay Drug Dev Technol, 4(4): 411-20. [Abstract] [Full-text]
2. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.
   Leuk Res, 30(11): 1443-6. [Abstract] [Full-text]
3. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
   Leuk Res, 30(11): 1365-70. [Abstract] [Full-text]
4. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
   Eur J Cancer, 42(14): 2277-85. [Abstract] [Full-text]
5. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
   Comp Biochem Physiol C Toxicol Pharmacol, 144(1): 85-92. [Abstract] [Full-text]
6. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
   Blood, 108(6): 1835-40. [Abstract] [Full-text]
7. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
   Blood, 108(6): 1809-20. [Abstract] [Full-text]
8. Somatic activation of KIT in distinct subtypes of melanoma.
   J Clin Oncol, 24(26): 4340-6. [Abstract] [Full-text]
9. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
   Clin Sci (Lond), 111(4): 233-49. [Abstract] [Full-text]
10. Imatinib inhibits spontaneous rhythmic contractions of human uterus and intestine.
    Eur J Pharmacol, 546(1): 177-81. [Abstract] [Full-text]
11. Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors.
    J Gastrointest Surg, 10(8): 1099-1105. [Abstract] [Full-text]
12. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Cancer Genet Cytogenet, 170(1): 54-7. [Abstract] [Full-text]
13. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
    Cancer Genet Cytogenet, 170(1): 16-23. [Abstract] [Full-text]
14. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
    Br J Dermatol, 155(4): 824-6. [Abstract] [Full-text]
15. Molecular medicine, the medicare drug benefit, and the need for cost control.
    J Am Geriatr Soc, 54(9): 1442-6. [Abstract] [Full-text]
16. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
    J Med Chem, 49(19): 5840-4. [Abstract] [Full-text]
17. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    J Med Chem, 49(19): 5759-68. [Abstract] [Full-text]
18. Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate.
    Circ Res, 99(6): 617-25. [Abstract] [Full-text]
19. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
    Bone Marrow Transplant, 38(7): 483-91. [Abstract] [Full-text]
20. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response?
    Leuk Res. [Abstract] [Full-text]
21. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.
    Lab Invest, 86(10): 981-6. [Abstract] [Full-text]
22. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
    Cancer Res, 66(18): 9153-61. [Abstract] [Full-text]
23. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
    Blood, 108(7): 2332-8. [Abstract] [Full-text]
24. Regression of Grade III Astrocytoma During the Treatment of CML with Imatinib Mesylate.
    Am J Ther, 13(5): 458-9. [Abstract] [Full-text]
25. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Curr Opin Oncol, 18(6): 578-83. [Abstract] [Full-text]
26. Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.
    Expert Opin Biol Ther, 6(10): 1011-22. [Abstract] [Full-text]
27. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Blood Cells Mol Dis, 37(2): 111-5. [Abstract] [Full-text]
28. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Vet Immunol Immunopathol, 114(1): 168-72. [Abstract] [Full-text]
29. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: A preliminary assessment.
    Blood Cells Mol Dis, 37(2): 116-24. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.